Next-Generation Molecular Diagnostic Platform: Powering Clinical and AI Infrastructure

GeneAtlas

Enabling early and timely disease detection
Ultra-multiplexity and ultra-sensitivity
Cost-effective, convenient and fully accessible solution

Timely

Empowers clinicians to make personalized treatment
decisions at the earliest possible stage

Multiplexity and Sensitivity

Dramatically increases sample throughput using
advanced microfluidics and 4th Gen PCR technology

Accessibility

Provides an accessible, cost-effective solution for prenatal screening, sepsis detection and multi-cancer diagnostic panels

Advancing Life Sciences

GeneAtlas provides a complete, end-to-end IVD ecosystem powered by our proprietary 4th Gen PCR technology.

GeneAtlas Platform
Rapid-cycling molecular diagnostic analyser engineered for the clinic, equiped with automated data processing and reporting

GeneAtlas PCR Universal Kit
Versatile reagent solutions for diverse areas

Clinical Test Kits
Sepsis
Prenatal
Multi-Cancer Early Detection (MCED)

Contact us for custom assay

Workflow in Action

We present a dynamic overview of our GeneAtlas Platform. From DNA partitioning to PCR cycles and target detection.

ABOUT MULTERA

Bridging the gap between ultra-multiplex screening and rapid diagnostic decision-making

Founded in 2025, Multera Limited is dedicated to developing GeneAtlas, a next-generation genomic intelligence platform designed to enable rapid, high-resolution, ultra-multiplex molecular analysis in decentralized clinical settings.

GeneAtlas directly responds to societal needs for earlier disease detection, accessible precision diagnostics, and resilient healthcare infrastructure. By lowering the barrier to high-resolution genomic analysis, the platform extends advanced molecular diagnostics beyond major metropolitan centres. In oncology and prenatal care, earlier and more comprehensive detection improves patient outcomes and reduces long-term healthcare burden. In critical disease like sepsis, earlier identification saves patients’ life.